Merih Çetinkaya

Prof. Merih Çetinkaya

Health Sciences University, Basaksehir Cam and Sakura City Hospital, Istanbul, İstanbul, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
Mehmet Yekta ONCELMehmet Yekta ONCEL
Mehmet Yekta ONCEL
IAIlke Mungan Akın
Ilke Mungan Akın
MKMehmet Kenan Kanburoglu
Mehmet Kenan Kanburoglu
CTCuneyt Tayman
Cuneyt Tayman
SCSenay Coskun
Senay Coskun
EKEsin Koc
Esin Koc

11 December 2008 in Journal of Perinatology
Verified
Journal Article
Closed access
MÇMerih Çetinkaya
Merih Çetinkaya
HÖH Özkan
H Özkan
NKN Köksal
N Köksal
SÇS Çelebi
S Çelebi
MHM Hacımustafaoğlu
M Hacımustafaoğlu

18 February 2014 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
HOHilal Ozkan
Hilal Ozkan
MÇMerih Çetinkaya
Merih Çetinkaya
NKNilgün Koksal
Nilgün Koksal
SCSolmaz Celebi
Solmaz Celebi
MHMustafa Hacımustafaoglu
Mustafa Hacımustafaoglu

1 August 2011 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
MÇMerih Çetinkaya
Merih Çetinkaya
HÖHilal Özkan
Hilal Özkan
NKNilgün Köksal
Nilgün Köksal
OAOkan Akacı
Okan Akacı
TÖTaner Özgür
Taner Özgür

1 November 2012 in Early Human Development
Verified
Journal Article
Closed access
MÇMerih Çetinkaya
Merih Çetinkaya
HOHilal Ozkan
Hilal Ozkan
NKNilgun Koksal
Nilgun Koksal

4 December 2010 in Neonatology
Verified
Journal Article
Closed access
MÇMerih Çetinkaya
Merih Çetinkaya
TATülin Alkan
Tülin Alkan
FOFadil Ozyener
Fadil Ozyener
IKIlker Mustafa Kafa
Ilker Mustafa Kafa
MKMustafa Ayberk Kurt
Mustafa Ayberk Kurt
NKNilgun Koksal
Nilgun Koksal
Background: Perinatal hypoxia-ischemia is a major cause of mortality and long-term neurological deficits. Objectives: The objective of this study was to compare the effects of two neuroprotective agents; magnesium sulfate and melatonin, administered alone or in combination, on brain infarct volume and TUNEL positivity in a neonatal hypoxic-ischemic (HI) rat model. Methods: After being anesthetized, 7-day-old pups (n = 80) underwent ischemia followed by exposure to hypoxia for 2 h. The pups were then divided equally and randomly into 4 groups in order to receive the vehicle (saline, control group), magnesium sulfate, melatonin or a combination of magnesium sulfate and melatonin. Treatments were administered intraperitoneally three times; the first being just before ischemia, the second after hypoxia and the third 24 h after the second dose. The pups were sacrificed on postnatal day 10, their brains harvested and evaluated for infarct volume and neuronal apoptosis. Results: Percent infarcted brain volume was significantly reduced in pups receiving the drugs (either magnesium sulfate, melatonin or their combination) compared with those receiving the vehicle. In addition, TUNEL staining showed markedly reduced numbers of TUNEL-positive cells per unit area in the CA1, CA3 and dentate gyrus regions of the hippocampus and in the cortex. However, no statistically significant differences were found regarding percent infarcted brain volume and number of TUNEL-positive cells among the drug-treated groups. Conclusions: Magnesium sulfate and melatonin, two agents acting at different stages of HI brain damage, administered either alone or in combination, significantly reduced the percent infarcted brain volume and TUNEL positivity, suggesting that these agents may confer a possible benefit in the treatment of infants with HI encephalopathy.